Oculis (NASDAQ:OCS) Earns Buy Rating from Chardan Capital

Chardan Capital reiterated their buy rating on shares of Oculis (NASDAQ:OCS) in a report released on Tuesday,Benzinga reports. Chardan Capital currently has a $28.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Monday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $28.80.

Oculis Stock Performance

OCS stock opened at $18.70 on Tuesday. Oculis has a one year low of $10.50 and a one year high of $18.72. The firm has a market cap of $757.42 million, a price-to-earnings ratio of -9.69 and a beta of -0.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm has a 50-day simple moving average of $16.38 and a two-hundred day simple moving average of $13.87.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.